Pegasys (Hoffman-La Roche Inc)
Pegasys (Hoffman-La Roche Inc) Brand names, Pegasys (Hoffman-La Roche Inc) Analogs
Pegasys (Hoffman-La Roche Inc) Brand Names Mixture
- No information avaliable
Pegasys (Hoffman-La Roche Inc) Chemical_Formula
C860H1353N227O255S9
Pegasys (Hoffman-La Roche Inc) RX_link
http://www.rxlist.com/cgi/generic3/pegasys.htm
Pegasys (Hoffman-La Roche Inc) fda sheet
Pegasys (Hoffman-La Roche Inc) msds (material safety sheet)
Pegasys (Hoffman-La Roche Inc) Synthesis Reference
No information avaliable
Pegasys (Hoffman-La Roche Inc) Molecular Weight
19241.1
Pegasys (Hoffman-La Roche Inc) Melting Point
61 oC (Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999))Davis JM, Narachi MA, Levine HL, Alton NK, Arakawa T. Conformation and stability of two recombinant human interferon-alpha analogs.
Pegasys (Hoffman-La Roche Inc) H2O Solubility
No information avaliable
Pegasys (Hoffman-La Roche Inc) State
Liquid
Pegasys (Hoffman-La Roche Inc) LogP
-0.336
Pegasys (Hoffman-La Roche Inc) Dosage Forms
Solution
Pegasys (Hoffman-La Roche Inc) Indication
For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma
Pegasys (Hoffman-La Roche Inc) Pharmacology
Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.
Pegasys (Hoffman-La Roche Inc) Absorption
No information avaliable
Pegasys (Hoffman-La Roche Inc) side effects and Toxicity
No information avaliable
Pegasys (Hoffman-La Roche Inc) Patient Information
BIOD00043.html
Pegasys (Hoffman-La Roche Inc) Organisms Affected
No information avaliable
